intrahepatic cholangiocarcinoma
Conditions
Interventions
imaging 
phenotypes, 
Gold Standard:pathological diagnosis
Index test:Serum 
clinical 
Sponsors
Eastern Hepatobiliary Surgery Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 78 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-78 years old; 2. The following patients received the first treatment: (1) Intrahepatic cholangiocarcinoma: cholangiocarcinoma with secondary or higher sources of bile ducts and no hilar invasion was pathologically diagnosed as intrahepatic bile duct carcinoma; Enhanced CT/MRI or PET-CT of the upper abdomen indicated negative retroperitoneal lymph nodes; (2) Hepatocellular carcinoma, without hilar invasion, was pathologically diagnosed as hepatocellular carcinoma, and enhanced CT/MRI or PET-CT in the upper abdomen indicated negative retroperitoneal lymph nodes; (3) Healthy people; 3. Child-pugh score of liver function <7; 4.ECOG score 0-1; 5. Did not receive systematic treatment for ICC and HCC, including systematic chemotherapy, targeted drug therapy such as sorafenib, Regonafenib, lenfatinib, donafenib, etc., as well as immunocheckpoint inhibitor treatment; 6. BCLC stages of HCC were stage 0, A and B, and CNLC stages were stage Ia, Ib and IIa. There was no portal vein or main hepatic artery invasion or extrahepatic metastasis. The AJCC8th staging of ICC is T1-T2, and there is no portal vein and hepatic artery trunk invasion and extrahepatic metastasis; 7. The ICC receiving surgical treatment was R0 resection; 8. Voluntary informed consent.
Exclusion criteria
Exclusion criteria: 1. Postoperative pathology indicated non-intrahepatic cholangiocarcinoma/non-hepatocellular carcinoma; 2. Had received chemotherapy, radiotherapy, targeting, immunotherapy, TACE, ablation and other treatments; 3. History of other malignant tumors; 4. Function of important organs is not complete; 5. A woman who is pregnant or breastfeeding; 6. Extrahepatic metastasis, portal vein or main hepatic artery invasion; 7. Underwent major surgery (as determined by the investigator) within 4 weeks prior to enrollment, or was expected to require major surgery during the study treatment period; 8. Gastrointestinal perforation, abdominal fistula or abdominal abscess in the previous 6 months; 9. Occurrence of thrombosis or thromboembolism events, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc. within the previous 6 months; 10. Failure to follow the study protocol for treatment or regular follow-up; 11. Any other researcher considers that they cannot be enrolled.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under Curve; | — |
Secondary
| Measure | Time frame |
|---|---|
| recurrence-free survival; | — |
Countries
China
Contacts
Public ContactKui Wang
Eastern Hepatobiliary Surgery Hospital
Outcome results
None listed